" class="no-js "lang="en-US"> Gandeeva Announces New Appointment to its Board of Directors
Monday, June 05, 2023

Gandeeva Therapeutics Announces Appointment of Dr. Brenda G. Cooperstone to its Board of Directors

Gandeeva Therapeutics, a biotechnology company focused on designing and developing precision therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the appointment of Brenda Cooperstone, MD, as an independent member of its Board of Directors. Dr. Cooperstone is a pharmaceutical executive with more than 20 years of experience in drug development. She most recently served as the Chief Development Officer, Rare Diseases and the Pennsylvania Site Head for Pfizer Inc.

“We are excited to welcome Dr. Cooperstone to Gandeeva’s Board of Directors,” said Sriram Subramaniam, Ph.D., Founder and CEO of Gandeeva Therapeutics. “Dr. Cooperstone brings significant clinical development, regulatory, and portfolio strategy experience to our team, and we are thrilled to work with her as we advance our pipeline of innovative medicines to the clinic.”

“I am delighted to join Gandeeva’s Board as the company works to achieve its groundbreaking vision of combining detailed structural understanding of proteins with cryo-EM and machine learning to develop a pipeline of differentiated drugs in oncology and other therapeutic areas,” remarked Dr. Cooperstone.

Prior to joining Gandeeva Therapeutics’ Board of Directors, Brenda Cooperstone held key leadership positions as Pfizer’s Chief Development Officer, Rare Diseases, as well as Site Head in Collegeville, PA. Dr. Cooperstone also held various leadership positions at Pfizer and Wyeth across different therapeutic areas from early to late-stage clinical development and global medical affairs. Dr. Cooperstone was a pediatric nephrologist at the Scottish Rite Children’s Medical Center, an immunology research fellow at the University of Pennsylvania’s Renal Electrolyte Section, and a clinical fellow in pediatric nephrology at Children’s Hospital of Philadelphia. Dr. Cooperstone earned her M.D. at McGill University and completed her clinical residency at the Montreal Children’s Hospital in pediatrics. Dr. Cooperstone also serves as an independent board member at Senti Biosciences.

  1. Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Read more
  2. Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Read more
  3. Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Read more
  4. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Read more
  5. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency Read more